Abstracts tagged "Co-morbidities"

Abstract Number: 3162 • 2015 ACR/ARHP Annual Meeting
Prevalence of Chronic Comorbidities in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Systemic Lupus Erythematosus: An Analysis of UK Biobank Data
Eftychia Bellou¹, Michael Cook², John Bowes¹, Jamie C Sergeant³, Anne Barton⁴, Terence W. O'Neill² and Suzanne M.M. Verstappen², ¹Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Centre for Musculoskeletal Research, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, The University of Manchester, Centre for Musculoskeletal Research, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ⁴The Kellgren Centre for Rheumatology, Central Manchester Foundation Trust, NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and systemic lupus erythematosus (SLE) are immune-mediated disorders and are associated with a number of…
Abstract Number: 3164 • 2015 ACR/ARHP Annual Meeting
Calcium Pyrophosphate Deposition Disease and Associated Medical Co-Morbidities in the Veteran Population
Crystal Kleiber Balderrama¹, Daniel S. Lans², Ann K. Rosenthal^1,3 and Christie M. Bartels⁴, ¹Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ²Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, WI, ³Division of Rheumatology, Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, WI, ⁴Medicine, Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI
Title: Calcium Pyrophosphate Deposition Disease and Associated Medical Co-Morbidities in the Veteran Population. Background/Purpose: Precipitation of calcium pyrophosphate dihydrate (CPP) crystals in articular tissues…
Abstract Number: 3257 • 2015 ACR/ARHP Annual Meeting
The Link Between DAS28 and the Short-Term Risk of Acute Coronary Syndrome in RA, and Its Driving Factors
Lotta Ljung^1,2, Thomas Frisell³ and Johan Askling^3,4, ¹Department of Medicine, Solna, Clinical epidemiology unit, Karolinska Institutet, Stockholm, Sweden, ²Department for Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ³Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology Unit, Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: The extent to which a short-term effect of the disease activity adds to the over-risk of coronary events in patients with Rheumatoid Arthritis (RA)…
Abstract Number: 29 • 2015 ACR/ARHP Annual Meeting
Development of Multimorbidity in Patients with Newly Diagnosed Rheumatoid Arthritis – a Population-Based Study
Helga Radner^1,2, Rishi Desai³, Theodore Tsacogianis⁴, Daniel H. Solomon⁵ and Seoyoung C. Kim⁶, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Department of Internal Medicine III; Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³PharmacoEpidemiology & PharmacoEconomics, Brigham and Women's Hospital, Boston, MA, ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA, ⁵Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁶Medicine/Rheumatology, University of Pennsylvenia, Philadelphia, PA
Background/Purpose: Limited information exists whether RA patients are likely to develop more morbid conditions after RA diagnosis compared to those without RA and the…
Abstract Number: 381 • 2015 ACR/ARHP Annual Meeting
Associations Between Vitamin D Insufficiency, Osteoporotic Fractures and Comorbidites
Eugenio Chamizo Carmona¹, Juan Jose Aznar Sánchez^1,2, Raul Veroz Gonzalez², Tamara Libertad Rodriguez Araya¹, Piter José Cossio Jimenez² and Sara María Rojas Herrera³, ¹Rheumatology, Hospital de Mérida, Mérida, Spain, ²Hospital de Mérida, Mérida, Spain, ³Rheumatolotgy, Hospital de Mérida, Mérida, Spain
Background/Purpose: Vitamin D deficiency is highly prevalence, especially in adults and elderly population. There is controversy about its relationship with increased cardiovascular risk, osteoporosis and…
Abstract Number: 659 • 2015 ACR/ARHP Annual Meeting
Does the Inclusion of Extra-Articular Manifestations Improve Validity of the Self-Administered Comorbidity Questionnaire Modified for Spondyloarthritis (SpA-SCQ)? Results from ASAS-Comospa
Ivette Essers^1,2, Carmen Stolwijk^1,2, Adrien Etcheto³, Anna Molto⁴, Filip van Den Bosch⁵, Désirée van der Heijde⁶, Robert B.M. Landewé^7,8, Astrid van Tubergen^1,2, Maxime Dougados^4,9 and Annelies Boonen^1,10, ¹School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, Netherlands, ²Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ³Cochin Hospital, Paris Descartes University, Paris, France, ⁴Hopital Cochin, Paris Descartes University, Paris, France, ⁵Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands, Leiden, Netherlands, ⁷Rheumatology, Atrium Medical Center, Heerlen, Netherlands, ⁸Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁹Rheumatology Department, Hôpital Cochin, Paris, France, ¹⁰Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: The self-administered comorbidity questionnaire (SCQ) was developed to understand the impact of 13 common comorbidities on functioning and resource utilisation. In patients with ankylosing…
Abstract Number: 2442 • 2014 ACR/ARHP Annual Meeting
Aligning Ethics with Digital Health Technologies and Shared Decision-Making: Interview Accounts of Patients and Clinicians
Anne F. Townsend^1,2,3,4, Paul Adam⁵, Jenny Leese⁶, Linda C. Li^6,7, Michael McDonald², Sheila Kerr⁸, Gordon Whitehead⁸ and Catherine Backman^6,9, ¹Qualitative Research, Arthritis Research Centre of Canada, Richmond, BC, Canada, ²Maurice Young Centre for Applied Ethics, School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, ³Occupational Science and Occupational Therapy, University of British Columbia, Vancouver, BC, Canada, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁶Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁷Physical Therapy, University of British Columbia, Vancouver, BC, Canada, ⁸Arthritis Patient Advisory Board, Richmond, BC, Canada, ⁹Department of Occupational Science & Occupational Therapy, University of British Columbia, Vancouver, BC, Canada
Background/Purpose Medical ethics evolves as health care develops. Digital health technologies are transforming health care delivery and patient and clinician relationships. Ethical approaches are shifting…
Abstract Number: 2113 • 2014 ACR/ARHP Annual Meeting
The Number of Morbidities Drives the Health Care Expenditures and Presence of a Musculoskeletal Condition Is Additionally Accountable for Higher Costs
Antje van der Zee-Neuen¹, Polina Putrik², Sofia Ramiro³, Andras Keszei⁴, Astrid M. Chorus⁵, Rob de Bie⁶ and Annelies Boonen⁷, ¹Internal Medicine, Rheumatology, Maastricht University, Maastricht, Netherlands, ²Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ³Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam & Hospital Garcia de Orta, Almada, Portugal, Amsterdam, Netherlands, ⁴Medical Informatics, RWTH Aachen University, Aachen, Germany, ⁵Netherlands Organization for Applied Scientific Research, Leiden, Netherlands, ⁶Epidemiology, Maastricht University, Maastricht, Netherlands, ⁷Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: In Europe, 70- 80% of all healthcare expenses are attributable to chronic diseases and a large part of these are musculoskeletal conditions (MSKC).Having >1…
Abstract Number: 1833 • 2014 ACR/ARHP Annual Meeting
Quality of Primary Care Management of Patients with and without Rheumatoid Arthritis (RA)
Jessica Widdifield¹, Claire Bombardier², Jacqueline Young¹, Noah Ivers³, R. Liisa Jaakkimainen⁴, Sasha Bernatsky⁵, J. Michael Paterson¹, J. Carter Thorne⁶, Pooneh S.Akhavan⁷, Debra Butt¹, Vandana Ahluwalia⁸ and Karen Tu¹, ¹Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴Sunnybrook Health Sciences Centre, Toronto, ON, Canada, ⁵Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁶Southlake Regional Health Centre, Newmarket, Newmarket, ON, Canada, ⁷Mount Sinai Hospital, Toronto, ON, Canada, ⁸William Osler Health Center, Brampton, ON, Canada
Background/Purpose: Little is known about the quality of care received by patients with multiple chronic conditions in primary care and whether quality care is different…
Abstract Number: 1844 • 2014 ACR/ARHP Annual Meeting
Identification of a Patient Phenotype Which Impacts Response to Therapy in Rheumatoid Arthritis Clinical Trials: Certolizumab Pegol Phase 4 Trial Data
Jeffrey R. Curtis¹, Melvin Churchill², Alan Kivitz³, Laura Gauer⁴, Christopher Herrem⁴, David Carter⁵, Jeffrey Melin⁴ and Yusuf Yazici⁶, ¹The University of Alabama at Birmingham, Birmingham, AL, ²Arthritis Center of Nebraska, Lincoln, NE, ³Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ⁴UCB Pharma, Smyrna, GA, ⁵UCB Pharma, Brussels, Belgium, ⁶New York University Hospital for Joint Diseases, New York, NY
Background/Purpose The PREDICT trial (NCT01255761) examined predictability of certolizumab pegol (CZP) treatment success at Week (Wk) 52 based on response at Wk12 assessed by RAPID3…
Abstract Number: 1428 • 2014 ACR/ARHP Annual Meeting
Comparison of Application of the European Society Cardiology, Adult Treatment Panel III, and ACC/AHA Guidelines for Cardiovascular Disease Prevention in a French Cohort of Rheumatoid Arthritis
Martin Soubrier¹, Zuzana Tatar², Maxime Chevreau³, Bruno Pereira⁴, Laure Gossec⁵, P Gaudin⁶ and Maxime Dougados⁷, ¹COMEDRA trial group, Paris, France, ²Centre Jean Perrin, Clermont Ferrand, France, ³Rheumatology, CHU Sud Hospital, Grenoble, France, ⁴Clinical research department, Clermont-Ferrand, France, ⁵Sorbonne Universités, UPMC Univ Paris 06, GRC-08, Institut Pierre Louis d’Epidémiologie et de Santé Publique, paris, France, ⁶CHU Hôpital Sud, Grenoble, France, ⁷RAID working group for EULAR, Zurich, Switzerland
Background/Purpose Cardiovascular risk (CVR) is increased in RA and should be evaluated annually. EULAR recommends using the SCORE equation to calculate risk, after applying a…
Abstract Number: 1313 • 2014 ACR/ARHP Annual Meeting
Comorbidity Patterns in Children with Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus: The Childhood Arthritis and Rheumatology Research Alliance Registry
Marc D. Natter¹, Mei-Sing Ong², Kenneth D. Mandl³, Laura Schanberg⁴, Yukiko Kimura⁵, Norman Ilowite⁶ and the CARRA Registry Investigators, ¹Intelligent Health Labs, Children's Hospital Boston, Boston, MA, ²Australian Institute of Health Innovation, University of New South Wales, Sydney, Australia, ³Intelligent Health Lab, Children's Hospital Boston, Boston, MA, ⁴Duke University, Durham, NC, ⁵Pediatric Rheumatology, Hackensack Univ Medical Ctr, Hackensack, NJ, ⁶Rheumatology, Children's Hospital Montefiore, Bronx, NY
Background/Purpose: Knowledge of co-occurring disease processes (comorbidities) is important for understanding disease pathogenesis, refining disease classifications, developing appropriate screening and prevention strategies, and determining overall…
Abstract Number: 553 • 2014 ACR/ARHP Annual Meeting
Comparison of Baseline Extra-Articular Manifestations, Comorbidities, and Long-Term Safety in Patients Treated with Adalimumab for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Joachim Sieper¹, Désirée van der Heijde², Nupun A. Varothai³ and Jaclyn K. Anderson³, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³AbbVie Inc., North Chicago, IL
Background/Purpose: To compare 1) extra-articular manifestations, 2) baseline comorbidities, and 3) adverse event (AE) rates with long-term adalimumab (ADA) therapy in patients (pts) treated in…
Abstract Number: 422 • 2014 ACR/ARHP Annual Meeting
Correlation of RAPID3, DAS28 and CDAI in Disease Activity and Effects of Education Level and Co-Morbid Diseases on This Assesment in RA
Kubilay Sahin¹, Yasar Karaaslan^2,3, Zeynep Ozbalkan¹, Ahmet Omma¹ and Nesibe Yesil¹, ¹Rheumatology, Ankara Numune Education and Research Hospital, Ankara, Turkey, ²Rheumatology, Hitit University, Corum, Turkey, ³Ankara Numune Training and Research Hospital, Ankara, Turkey
Background/Purpose RAPID3 is an activity index based on only the patient's report in RA. It doesn’t require joint counts and it isn’t time consuming. Therefore…
Abstract Number: 341 • 2014 ACR/ARHP Annual Meeting
Death Receptor 3 Causes Vascular Dysfunction in a Murine Model of Rheumatoid Arthritis
Jessica O Williams¹, Eddie C.Y. Wang², Derek Lang¹ and Anwen S. Williams², ¹Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom, ²Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom
Background/Purpose: Increased cardiovascular (CV) risk is prevalent in several forms of inflammatory arthritides. The mechanisms that regulate CV disease during early inflammatory arthritis are ill-defined.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].